Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study
Michael Joseph Boyer, Mehmet Alı Nahıt Şendur, Delvys Rodríguez‐Abreu et al. · Journal of Clinical Oncology · 2021
PURPOSE Pembrolizumab monotherapy is standard first-line therapy for metastatic non–small-cell lung cancer (NSCLC) with programmed death ligand 1 (PD-L1) tumor proportion score (TPS) ≥ 50% without actionable driver mutations. It is not known whether adding ipilimumab to pembrolizumab improves efficacy over pembrolizumab alone in this population. METHODS In the randomized, double-blind, phase III KEYNOTE-598 trial (ClinicalTrials.gov identifier: NCT03302234 ), eligible patients with previously untreated metastatic NSCLC with PD-L1 TPS ≥ 50% and no sensitizing EGFR or ALK aberrations were randomly allocated 1:1 to ipilimumab 1 mg/kg or placebo every 6 weeks for up to 18 doses; all participants received pembrolizumab 200 mg every 3 weeks for up to 35 doses. Primary end points were overall survival and progression-free survival. RESULTS Of the 568 participants, 284 were randomly allocated to each group. Median overall survival was 21.4 months for pembrolizumab-ipilimumab versus 21.9 months for pembrolizumab-placebo (hazard ratio, 1.08; 95% CI, 0.85 to 1.37; P = .74). Median progression-free survival was 8.2 months for pembrolizumab-ipilimumab versus 8.4 months for pembrolizumab-placebo (hazard ratio, 1.06; 95% CI, 0.86 to 1.30; P = .72). Grade 3-5 adverse events occurred in 62.4% of pembrolizumab-ipilimumab recipients versus 50.2% of pembrolizumab-placebo recipients and led to death in 13.1% versus 7.5%. The external data and safety monitoring committee recommended that the study be stopped for futility and that participants discontinue ipilimumab and placebo. CONCLUSION Adding ipilimumab to pembrolizumab does not improve efficacy and is associated with greater toxicity than pembrolizumab monotherapy as first-line treatment for metastatic NSCLC with PD-L1 TPS ≥ 50% and no targetable EGFR or ALK aberrations. These data do not support use of pembrolizumab-ipilimumab in place of pembrolizumab monotherapy in this population.
Cited by 247 works. doi:10.1200/jco.20.03579 Open-access PDF
Authors
- Michael Joseph Boyer
- Mehmet Alı Nahıt Şendur
- Delvys Rodríguez‐Abreu
- Keunchil Park
- Dae Ho Lee
- İrfan Çiçin
- Perran Fulden Yumuk
- Francesco Orlandi
- Ticiana A.B. Leal
- Olivier Molinier
- Nopadol Soparattanapaisarn
- Adrian Langleben
- Raffaele Califano
- Balazs Medgyasszay
- Te‐Chun Hsia
- Gregory A. Otterson
- Lu Xu
- Bilal Piperdi
- Ayman Samkari
- Martin Reck
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- Toxicity and response criteria of the Eastern Cooperative Oncology Group
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden